OptimizeRx Reports Record Q4 Profit, 19% FY Revenue Growth, and $10M Share Buyback
OPRX sits 96% above its 52-week low of $3.991 on elevated volume (2.8× avg).
Summary
OptimizeRx reported robust fourth quarter and full-year 2025 financial results, highlighted by record GAAP net income of $5.0 million for Q4 and $5.1 million for the full year, a significant turnaround from prior year losses. Full-year revenue increased 19% to $109.4 million, and Adjusted EBITDA reached $24.3 million, demonstrating strong profitable growth and achieving the "Rule of 40" benchmark. The company also updated its 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million, signaling continued confidence. Further bolstering shareholder value, the Board authorized a $10 million share repurchase program, which is a material capital allocation decision for a company of its size. Traders will be watching for continued execution on guidance and the impact of the share repurchase program, especially given potential market volatility and MFN pricing uncertainty mentioned by management.
At the time of this announcement, OPRX was trading at $7.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $140.4M. The 52-week trading range was $3.99 to $22.25. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.